Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 3
2021 2
2022 1
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Real-world data of the use and experience of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura: Case series.
Albanell-Fernández M, Monge-Escartín I, Carcelero-San Martín E, Riu Viladoms G, Ruiz-Boy S, Lozano M, Soy D, Moreno-Castaño AB, Diaz-Ricart M, Cid J. Albanell-Fernández M, et al. Among authors: monge escartin i. Transfus Apher Sci. 2023 Jun;62(3):103722. doi: 10.1016/j.transci.2023.103722. Epub 2023 May 8. Transfus Apher Sci. 2023. PMID: 37169697 Review.
At-Home Foscarnet Administration in Patients with Cytomegalovirus Infection Post-Allogeneic Stem Cell Transplantation: A Unicentric, Safe, and Feasible Program.
Ruiz-Boy S, Pedraza A, Prat M, Salas MQ, Carcelero E, Riu-Viladoms G, Suárez-Lledó M, Monge-Escartín I, Rodríguez-Lobato LG, Martínez-Roca A, Rovira M, Martínez C, Gallego C, Urbano-Ispizua Á, Sánchez J, Marcos MÁ, Fernández-Avilés F. Ruiz-Boy S, et al. Among authors: monge escartin i. Pharmaceuticals (Basel). 2023 Dec 18;16(12):1741. doi: 10.3390/ph16121741. Pharmaceuticals (Basel). 2023. PMID: 38139867 Free PMC article.
Assessment of the change of antiemetic prophylaxis from double to triple combination in patients with high dose carboplatin chemotherapy.
Albanell-Fernández M, Pérez Sánchez Á, Monge-Escartín I, Riu-Viladoms G, Rodríguez Mues MC, Corominas Bosch ML, Gaba García L, Rollán NB, Reguart N, Soy Muner D, Carcelero San Martín E. Albanell-Fernández M, et al. Among authors: monge escartin i. J Oncol Pharm Pract. 2023 Aug 10:10781552231194077. doi: 10.1177/10781552231194077. Online ahead of print. J Oncol Pharm Pract. 2023. PMID: 37563932
Primary care electronic medication record discrepancies in patients starting treatment at a hospital-based ambulatory care pharmacy and impact on prevalence of potential drug-drug interactions.
González-Colominas E, López-Mula C, Martínez-Casanova J, Luque S, Conde-Estévez D, Monge-Escartín I, Ferrández O. González-Colominas E, et al. Among authors: monge escartin i. Eur J Hosp Pharm. 2023 Nov;30(6):333-339. doi: 10.1136/ejhpharm-2021-002963. Epub 2022 Jan 27. Eur J Hosp Pharm. 2023. PMID: 35086803
ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer.
Griguolo G, Brasó-Maristany F, González-Farré B, Pascual T, Chic N, Saurí T, Kates R, Gluz O, Martínez D, Paré L, Tsvetkova V, Pesantez D, Vidal M, Adamo B, Muñoz M, Galván P, Barberá L, Cuatrecasas M, Christgen M, Kreipe H, Monge-Escartín I, Villagrasa P, Soy D, Giarratano T, Dieci MV, Conte P, Harbeck N, Guarneri V, Prat A. Griguolo G, et al. Among authors: monge escartin i. Cancers (Basel). 2020 Jul 14;12(7):1902. doi: 10.3390/cancers12071902. Cancers (Basel). 2020. PMID: 32674482 Free PMC article.
Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockage.
Conde-Estévez D, Monge-Escartín I, Ríos-Hoyo A, Monzonis X, Echeverría-Esnal D, Moliner L, Duran-Jordà X, Taus Á, Arriola E. Conde-Estévez D, et al. Among authors: monge escartin i. J Chemother. 2021 Feb;33(1):32-39. doi: 10.1080/1120009X.2020.1849488. Epub 2020 Dec 3. J Chemother. 2021. PMID: 33267748
Impact of HCV cure with drug-acting antivirals in the use of concomitant medication and lipid profile: follow-up data 2 years after the sustained virological response.
González-Colominas E, Batlle M, Monge-Escartín I, Duran X, Viu A, de Antonio-Cuscó M, Grau S, Bessa X, Carrión JA. González-Colominas E, et al. Among authors: monge escartin i. Eur J Gastroenterol Hepatol. 2021 Feb 1;32(2):214-222. doi: 10.1097/MEG.0000000000001714. Eur J Gastroenterol Hepatol. 2021. PMID: 32195695